【7 for all mankind santa monica】Morgan Stanley Downgrades Hologic On Tough Cynosure Recovery, Surgery Business Risks

Although

Hologic,7 for all mankind santa monica Inc.

(NASDAQ:

HOLX

) acquired

Cynosure

to achieve a higher weighted average market growth rate, Cynosure's main businesses have not delivered as expected, according to Morgan Stanley.

The Analyst

Morgan Stanley’s David Lewis downgraded

Hologic

from

Equal-weight to Underweight

and cut the price target from $44 to $39.

The Thesis

Hologic diversified into aesthetics with its purchase of Cynosure, with expectations of generating higher WAMGR, Lewis said in the Wednesday downgrade note.

Yet MonaLisa Touch and SculpSure — which drove almost all of Cynosure’s growth prior to the acquisition — have not returned to their pre-acquisition levels, the analyst said.

The body sculpting channel is showing signs of saturation, and the company's women’s health strategy appears flawed given the FDA’s latest scrutiny of vaginal rejuvenation, Lewis said.

Competition for NovaSure will intensify if Channel Medsystem’s Cerene snags FDA approval in mid-2019, he said.

Hologic operates in slower growth end markets versus its peers and has a WAMGR of around 3.5 percent, which is significantly below that the competition's 5 percent, the analyst said.

“A structural 3-percent organic and 8-percent EPS growth profile is below peers at 5-6 percent organic and double-digit earnings growth, which suggests Hologic is likely to relatively underperform peers."

Price Action

Hologic shares were trading down 6.45 percent at $38.45 at the time of publication Wednesday.

Related Links:

Hologic Downgraded By BofA As Cynosure Headwinds Persist

Hologic: Meet Goldman Sach's New 'Conviction Buy'

Photo courtesy of Hologic.

Latest Ratings for HOLX

Jan 2019

Morgan Stanley

Downgrades

Equal-Weight

Underweight

Nov 2018

RBC Capital

Maintains

Sector Perform

Sector Perform

Oct 2018

Morgan Stanley

Maintains

Equal-Weight

Equal-Weight

View More Analyst Ratings for HOLX

View the Latest Analyst Ratings

See more from Benzinga

JPMorgan Sees Buying Opportunity In Torchmark

Analyst: NeuroMetrix Benefits From Alternative Pain Management Trend

Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

View comments